Product Biomarkers

Solutions Accelerated by IsoPlexis

  • Cell Engineering & Therapy

Apply PSI™ to CAR T-cell product release in a way that correlates to in vivo activity1

Detect the potent functional immune cell subsets that drive response and accelerate translational research.

Download application highlight

Research Area

Development Stage

Prediction

Goal

Identify pre-infusion correlates to in vivo activity of cell therapy and patient outcome

How our Award-Winning IsoLight Single-Cell System is Making a Difference

polyfunctional cell

Solution

IsoPlexis’ PSI is able to stratify responders and non-responders

polyfunctional cell

Finding

Polyfunctional strength was found to correlate with objective response to CAR-T cell therapy, where other pre-infusion metrics did not

follow our data

Follow Our Data

See the latest published data in Cell Therapy

PSI of the pre-infusion CAR-T cell products showed significant correlation with the objective response of patients. The PSI, measured across a cohort of 20 patients, combined the CD4+ and CD8+ CAR-T response to CD19-K562 stimulation.

The average PSI of the responder subgroup was more than twice as high as the PSI of the non-responders, a difference that was shown to be statistically significant (p = 0.0119).1

Download application highlight
PSI Predicts Clinical Outcomes

Solution

Detect Critical Differences

PSI outperformed other pre-infusion metrics, including IFN-g co-culture cytokine intensity, ratio of CD4+ to CD8+ T cells, and various T cell phenotype frequencies.1

PSI was the only metric that statistically differentiated responding from non-responding patients. The correlation of PSI with clinical outcome indicates the metric’s potential as a biomarker for guiding personalized CAR-T cell treatments and predicting therapeutic efficacy.1

PSI vs. Other Pre-Infusion Metrics

Request a Seminar

Request a Seminar
Discover IsoLight